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ARTICLE
Improving Phenotypic Prediction by Combining
Genetic and Epigenetic Associations
Sonia Shah,1,2,14 Marc J. Bonder,3,14 Riccardo E. Marioni,1,4,5 Zhihong Zhu,1 Allan F. McRae,1,2
Alexandra Zhernakova,3 Sarah E. Harris,4,5 Dave Liewald,4 Anjali K. Henders,6
Michael M. Mendelson,7,8,9 Chunyu Liu,10 Roby Joehanes,11 Liming Liang,12 BIOS Consortium,
Daniel Levy,9 Nicholas G. Martin,6 John M. Starr,4,13 Cisca Wijmenga,3 Naomi R. Wray,1 Jian Yang,1
Grant W. Montgomery,6,14 Lude Franke,3,14 Ian J. Deary,4,13,14 and Peter M. Visscher1,2,4,14,*
We tested whether DNA-methylation profiles account for inter-individual variation in body mass index (BMI) and height and whether
they predict these phenotypes over and above genetic factors. Genetic predictors were derived from published summary results from the
largest genome-wide association studies on BMI (n ~ 350,000) and height (n ~ 250,000) to date. We derived methylation predictors by
estimating probe-trait effects in discovery samples and tested them in external samples. Methylation profiles associated with BMI in
older individuals from the Lothian Birth Cohorts (LBCs, n ¼ 1,366) explained 4.9% of the variation in BMI in Dutch adults from the
LifeLines DEEP study (n ¼ 750) but did not account for any BMI variation in adolescents from the Brisbane Systems Genetic Study
(BSGS, n ¼ 403). Methylation profiles based on the Dutch sample explained 4.9% and 3.6% of the variation in BMI in the LBCs and
BSGS, respectively. Methylation profiles predicted BMI independently of genetic profiles in an additive manner: 7%, 8%, and 14% of
variance of BMI in the LBCs were explained by the methylation predictor, the genetic predictor, and a model containing both, respec-
tively. The corresponding percentages for LifeLines DEEP were 5%, 9%, and 13%, respectively, suggesting that the methylation profiles
represent environmental effects. The differential effects of the BMI methylation profiles by age support previous observations of age
modulation of genetic contributions. In contrast, methylation profiles accounted for almost no variation in height, consistent with a
mainly genetic contribution to inter-individual variation. The BMI results suggest that combining genetic and epigenetic information
might have greater utility for complex-trait prediction.Introduction
Obesity is a major risk factor for a number of chronic
diseases, including diabetes, cardiovascular diseases, and
cancer.1–4 Once considered a health burden only in
high-income countries, it is a growing epidemic that is
dramatically on the rise in low- and middle-income
countries, particularly in urban settings. Knowledge of
the genetic and environmental contributors to obesity
is necessary for developing effective strategies to
reduce its global burden. Body mass index (BMI) is a
commonly used measure for quantifying obesity.
Although many genetic determinants of BMI have been
identified by large genome-wide association studies
(GWASs),5 only about 10% of the inter-individual varia-
tion in BMI has been explained by genetic factors. With
recent advances in high-throughput genomic technolo-
gies, researchers are now turning to epigenetics as a way
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Thenvironment and their contribution to complex traits
and diseases.
Epigenetics refers to the regulatory processes that con-
trol gene expression without altering the DNA sequence.
The most studied epigenetic process is DNA methylation,
the reversible addition of a methyl group primarily to a
cytosine residue at a CpG dinucleotide. Because epige-
netic variation reflects both genetic and environmental
exposures, there is potential to identify novel disease-
associated genes and pathways that might not be discov-
ered through genetic studies alone. Methylome-wide
association studies (MWASs), using methylation arrays
such as the Illumina Infinium HumanMethylation450
array, have already begun to identify genomic CpG sites
whose methylation levels are associated with BMI.6
DNA-methylation levels at specific CpG sites have already
shown to be accurate predictors of age and smoking
status,7–9 and such phenotypic prediction could extend
to complex traits and disease and potentially improvelia; 2University of Queensland Diamantina Institute, Translational Research
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prediction over genetic information. The ability of DNA-
methylation profiles to predict cross-sectionally complex
traits independently of genotypic information has not
yet been explored. Here, we investigate whether DNA-
methylation profiles associate with BMI and height inde-
pendently of genotypic information. BMI and height
represent two complex traits with different relative contri-
butions of genetics and environment to inter-individual
variance.10–13 Heritability estimates for BMI are high but
vary (0.3–0.8) among twin and family studies. The genetic
contribution appears to vary with age, such that it has a
greater influence during childhood than during adult
life.10 In contrast, height is known to have a mostly ge-
netic contribution; heritability estimates from both twin
and family studies are consistently around 0.8 in nutri-
tionally replete societies.11–13 These findings suggest that
epigenetic contributions might be greater for BMI than
for height.
Therefore, the present study aimed to test the relative
contributions of DNA-methylation status and genetic
variation to inter-individual variation in BMI and height.
We hypothesized a priori that after genetic determinants
of phenotype are accounted for, DNA methylation will
provide a far more substantial contribution to inter-
individual variation in BMI than to variation in height.
To this end, we first performed an MWAS for BMI
and height in two independent datasets; the discovery
sample comprised 1,366 older individuals from two
Scottish birth cohorts (the Lothian Birth Cohorts [LBCs]
of 1921 [n ¼ 446; mean age 79.1 5 0.6 years] and 1936
[n ¼ 920; mean age 69.55 0.8 years]), and the validation
sample was the LifeLines DEEP cohort of Dutch adult
individuals (n ¼ 750; mean age 45.5 5 13.3 years).
For each trait, we generated methylation-profile scores
(a weighted sum of the methylation levels at associated
CpG sites) in the validation cohort on the basis of the
observed CpG associations in the discovery cohort, and
we estimated the proportion of height and BMI variance
accounted for by these DNA-methylation profiles. We
also determined whether the methylation-profile scores
were associated with the two traits independently of
genetic-profile scores (weighted sum of associated effect
alleles of associated SNPs) on the basis of results from
the most recent BMI and height meta-GWASs carried
out by the Genetic Investigation of Anthropometric Traits
(GIANT) consortium.14
In adults, the BMI cutoffs that define obesity are not
linked to age and do not differ for men and women,
whereas in children BMI varies with age and sex.15
Therefore, methylation changes associated with BMI in
adults might not necessarily reflect those observed in
children or adolescents. To investigate this further, we
tested whether BMI-associated methylation changes
observed in the adults of the LBCs and LifeLines DEEP
cohort were predictive of BMI in adolescents from the Bris-
bane Systems Genetics Study (BSGS; n ¼ 403; mean age
14.0 5 2.4).76 The American Journal of Human Genetics 97, 75–85, July 2, 2015Material and Methods
Cohorts
LBCs
The LBCs comprise individuals born in 1921 (LBC1921) and 1936
(LBC1936), and most of these individuals were participants in the
Scottish Mental Surveys (SMSs) of 1932 and 1947, respectively,
when nearly all 11-year-old children in Scotland completed an
IQ-type test in school. The LBC studies provide follow up of surviv-
ing SMS participants who are living in the Lothian region (Edin-
burgh city and outskirts) of Scotland.16–18 The LBC studies focus
on the determinants of people’s cognitive aging differences and
collect detailed information on cognitive, biomedical, lifestyle,
socio-demographic, behavioral, physical, and psychological fac-
tors. An overview of the data collected in the LBCs can be found
in the cohorts’ profile article.18 The current study draws upon the
baseline examinations (including blood-sample collection and
phenotypic measurements) of 550 LBC1921 participants recruited
in 1999–2001 (average age of 79 years) and 1,091 LBC1936 partic-
ipants recruited in 2004–2007 (average age of 70 years).
LifeLines DEEP
This is a sub-cohort (n ¼ 752, recruited in 2013) of the LifeLines
study,19 the latter of which is a multi-disciplinary prospective pop-
ulation-based cohort study examining the health and health-
related behaviors of 167,729 persons living in the north of the
Netherlands in a unique three-generation design. It employs a
broad range of investigative procedures in assessing the biomed-
ical, socio-demographic, behavioral, physical, and psychological
factors contributing to the health and disease of the general pop-
ulation and has a special focus on multi-morbidity and complex
genetics. A full description of the LifeLines DEEP study can be
found in the paper describing the cohort and data.19
BSGS
The BSGS is a study on adolescent twins comprising a total of 962
individuals from 314 families of European descent,20 and a subset
of these individuals have DNA-methylation data (614 individuals
from 177 families). Families consist of adolescent monozygotic
(MZ) and dizygotic (DZ) twins, their siblings, and their parents.
The BSGS comprises a sub-sample from a larger and continuing
study on families with adolescent twins. Recruitment commenced
in 1992. A full description of the BSGS cohort has been previously
provided.20,21Ethics
Ethics permission for LBC1921 was obtained from the Lothian
Research Ethics Committee (wave 1: LREC/1998/4/183). Ethics
permission for LBC1936 was obtained from the Multi-Centre
Research Ethics Committee for Scotland (wave 1: MREC/01/0/
56) and the Lothian Research Ethics Committee (wave 1: LREC/
2003/2/29). The BSGS was approved by the Queensland Institute
for Medical Research Human Research Ethics Committee. The
LifeLines DEEP study was approved by the ethical committee of
the University Medical Centre Groningen (document no. METC
UMCG LLDEEP: M12.113965). For all studies, written consent
was obtained from all participants.Phenotypic Measurements
LBCs
Weight and height were measured in the LBCs by a trained nurse
according to a standardized protocol. Participants were asked to re-
move their shoes before a seca stadiometer was used to assess
height in centimeters. Weight (after participants removed shoes
and outer clothing) was measured in kilograms by electronic
seca scales, which provided digital readouts.
LifeLines DEEP
Height was measured without shoes by the seca 222 stadiometer.
Weight was measured without shoes and heavy clothing by the
seca 761 scale. All measurements were performed by a trained
research nurse.
BSGS
Height and weight were both measured clinically with a stadiom-
eter and accurate scales, respectively. Anthropometric measure-
ments were only available for the offspring.
Complete blood cell counts (lymphocytes, monocytes, neutro-
phils, eosinophils, and basophils) were measured in the LBCs
and LifeLines cohort.
DNA Methylation
Whole-blood samples were collected at the same time as pheno-
typic measurements in all studies. Extracted DNA was profiled
with the Infinium HumanMethylation450 BeadChip,22 and data
were available on 752 LifeLines DEEP participants, 1,518 LBC par-
ticipants (514 from LBC1921 and 1,004 from LBC1936), and 614
BSGS participants. For each of the LBCs and the LifeLines DEEP
cohort, samples were randomized on 96-well plates, and methyl-
ation arrays were run in a single experiment to minimize batch ef-
fects. Low-quality probes and samples were excluded from further
analysis as described below.
LBC DNA-Methylation Quality Control
Details of DNA extraction and methylation profiling are described
elsewhere.23 Background correction of the raw intensity data and
generation of the methylation beta values were done with the R
minfi package. Quality-control (QC) steps included the removal
of probes with a low (<95%) detection rate at p < 0.01. Array con-
trol probes were inspected manually, and low-quality samples
(e.g., samples with inadequate hybridization, bisulfite conversion,
nucleotide extension, or staining signal) were removed. Samples
with a low call rate according to the Illumina-based threshold
(samples with <450,000 probes detected at p < 0.01) were
removed. LBC samples had been genotyped with the Illumina
610-Quadv1 genotyping platform. Genotype information from
the 65 SNP control CpG probes on the methylation chip were
cross-validated with those from the genotyping chip with the R
wateRmelon package. Where there was low correspondence, sam-
ples were excluded (n ¼ 9). We also excluded eight participants
whose reported sex did not match their predicted sex according
to methylation levels for probes on the X and Y chromosomes.
LifeLines DEEP DNA-Methylation QC
Details of DNA extraction and methylation profiling are described
elsewhere.19 Probe QC, background correction, color correction,
and normalization were performed with a custom pipeline based
on the pipeline by Tost and Touleimat.24 All methylation probes
were re-mapped to the human genome (hg37, UCSC Genome
Browser),25 and both poorly mapping probes and probes with a
SNP in the single-base extension side (according to GoNL26)
were removed in the same step. Data were normalized with
DASEN.27
BSGS DNA-Methylation QC
Details of DNA extraction, methylation profiling, and methyl-
ation QC are provided elsewhere.21
In all cohorts, non-autosomal probes and probes with underly-
ing SNPs at the target CpG site (according to Illumina annotation)
were excluded from further analysis. Methylation levels are pre-Thsented as beta values, which range between 0 and 1, where a value
of 0 indicates that all copies of the CpG site in the sample
were completely unmethylated (no methylated molecules were
measured), and a value of 1 indicates that every copy of the site
was methylated. Beta values were then processed as follows in
all cohorts. The beta values were logit transformed: log (beta/
(1  beta). For removal of variation due to batch effects and cova-
riates, the logit-transformed beta values were regressed onto the
technical variables (plate, array, and array position) and covariates
(sex and age for the main analysis; in addition, cell count was
adjusted in a sensitivity analysis in the LBCs and LifeLines DEEP
cohort). Residuals from this linear regression were inverse-normal
transformed and used in all subsequent analyses.
Genotyping
Genotype data were available for all samples with DNA-methyl-
ation data in the three cohorts. The LBC and BSGS samples
were genotyped with the Illumina Human610-Quad v1.0
genotyping platform, and data were available on all partici-
pants with DNA-methylation data. After QC, genotyped data
were imputed with 1000 Genomes Phase 1 version 328 and
IMPUTE2.29,30 The LifeLines DEEP samples were genotyped with
the HumanCytoSNP-12 BeadChip and the ImmunoChip,31 a
customized Illumina Infinium array. The data were merged and
subsequently imputed with GoNL26,32 and IMPUTE2.29,30 Details
of QC in each cohort are described below.
LBC Genotyping QC
DNA samples from each individual were genotyped with the Illu-
mina Human610-Quad BeadChip. Individuals were excluded on
the basis of unresolved gender discrepancy, relatedness, call rate
(%0.95), and evidence of non-European descent. SNPs were
included in the analyses if they met the following conditions:
call rateR 0.98, minor allele frequencyR 0.01, and Hardy-Wein-
berg equilibrium test with p R 0.001.
LifeLines DEEP Genotyping QC
Details of DNA extraction, genotyping, and QC are provided else-
where.19
BSGS Genotyping QC
DNA samples from each individual were genotyped by the Scien-
tific Services Division at deCODE Genetics (Iceland) with the
Illumina Human610-Quad BeadChip. Genotypes were called
with the Illumina BeadStudio software. A detailed description of
genotyping QC can be found elsewhere.20,33
Methylome-wide Association Analysis in the LBCs and
LifeLines DEEP Cohort
The BMI and height phenotypes were adjusted for sex and age and
standardized for the generation of Z scores. Linear regression anal-
ysis was used to test the association between each CpG probe
(independent variable) and the BMI or height Z score phenotype
(dependent variable).
Methylation-Profile Scores for BMI and Height
In the LBCs and LifeLines DEEP cohort, we first selected CpG
probes on the basis of a Bonferroni-corrected association p value
threshold (p < 0.05/[number of probes]). To remove redundant
CpG probes from the methylation-profile score, if multiple probes
passed the p value threshold and had a pairwise correlation greater
than 0.1 within a 500-bp window, we selected only the most sig-
nificant probe for the score. The choice of correlation threshold
and window size was based on previous studies that investigatede American Journal of Human Genetics 97, 75–85, July 2, 2015 77
Table 1. Summary of MWAS and GWAS Prediction Analyses
Trait
Cohort
Location of ResultsProbe Selection Effect-Size Estimation Prediction
MWAS Prediction
BMI LifeLines DEEP LifeLines DEEP LBC Figure 1
BMI LBC LBC LifeLines DEEP Figure 1
BMI Framingham LifeLines DEEP LBC Figure S4
BMI Framingham LBC LifeLines DEEP Figure S4
BMI LifeLines DEEP LifeLines DEEP BSGS Figure 2
BMI LBC LBC BSGS Figure 2
BMI Framingham LifeLines DEEP BSGS Figure 2
BMI Framingham LBC BSGS Figure 2
Height LifeLines DEEP LifeLines DEEP LBC Figure 1
Height LBC LBC LifeLines DEEP Figure 1
GWAS Prediction
BMI GIANT 2015 GIANT 2015 LBC Figure 1
BMI GIANT 2015 GIANT 2015 LifeLines DEEP Figure 1
BMI GIANT 2015 GIANT 2015 BSGS Figure 2
Height GIANT 2014 GIANT 2014 LBC Figure 1
Height GIANT 2014 GIANT 2014 LifeLines DEEP Figure 1pairwise probe correlation as a function of the distance between
probes.34,35 BMI and height methylation-profile scores were calcu-
lated as the weighted sum of the selected CpG methylation levels
(the weights for each CpG probe were the effect sizes from the
MWAS). We used selected probes and effect sizes from the LBC
MWAS to generate a methylation-profile score in the LifeLines
DEEP cohort, and vice versa.
For BMI, as a secondary replication cohort, we generated an
additional methylation-profile score, whereby we selected probes
on the basis of results from a larger, independent MWAS on BMI
in the Framingham Heart Study (n ¼ 2,377; mean age 67 5 9
years; age range ¼ 40–93 years; M.M.M., unpublished data). In
this analysis, 78 CpG probes had an association p value <
1.22 3 107 (Bonferroni correction for 409,403 probes) and were
selected for generating a BMI methylation-profile score. To
generate a Framingham-based methylation score in the LBCs, we
derived effect sizes for these 78 probes from the LifeLines DEEP
MWAS, whereas we derived effect sizes from the LBC MWAS to
generate the score in the LifeLines DEEP cohort.
Genetic-Profile Score for BMI and Height
We used SNP genotype data to calculate genetic-profile scores for
BMI and height. SNPs andweights (effect sizes) used for generating
the genetic-profile scores (the weighted sum of the effect allele
count) were based on the GIANT meta-GWAS for BMI in
~350,000 individuals14 and for height in ~250,000 individuals.36
It is important to note that none of the LBC, LifeLines DEEP, or
BSGS participants were part of the GIANT meta-GWAS, so discov-
ery bias was not an issue. Prior testing in an independent cohort
indicated that using all HapMap3 SNPs provided the best predictor
for BMI,14 whereas SNPs that had a p value < 5 3 105 and that
were selected with the GCTA-COJO (conditional and joint78 The American Journal of Human Genetics 97, 75–85, July 2, 2015genome-wide analysis) function in the GCTA software37 provided
the best predictor for height.14,36Proportion of Phenotypic Variance Explained in the
LBCs and LifeLines DEEP Cohort
Using linear regression, in each cohort we estimated how much
variance in the sex- and age-adjusted BMI and height phenotypes
(adjusted R2) was explained by the methylation- and genetic-pro-
file scores, both individually and combined. We also looked for
any evidence of interaction between the methylation- and ge-
netic-profile scores. For each trait in each cohort, we ran the
following four regression models and extracted the proportion of
variance explained from each:
Model 1: trait ~ MWAS score
Model 2: trait ~ GWAS score
Model 3: trait ~ MWAS score þ GWAS score
Model 4: trait ~ MWAS score þ GWAS score þ (MWAS score 3
GWAS score)
We used an ANOVA to test whether the interaction model
(model 4) explained significantly more of the variation in the
phenotype than the additive model (model 3). A summary of
the cross-cohort GWAS and MWAS predictions is presented in
Table 1.Proportion of Variance Explained in BMI of
Adolescent Individuals
We generated five methylation scores in the BSGS individuals and
report how much of the variation in sex- and age-adjusted BMI
was explained by each of the scores: (1) probe selection and
Table 2. Cohort Characteristics of the LBC and LifeLines DEEP
Participants at the Time of DNA-Methylation Assays
Cohort
LBC1936 LBC1921 LifeLines DEEP BSGS
n 920 446 752 403
Age (years) 69.5 5 0.8 79.1 5 0.6 45.5 5 13.3 14.0 5 2.4
Female 49.5% 60.5% 57.8% 48.1%
BMI (kg/m2) 27.8 5 4.4 26.2 5 4.0 25.4 5 4.2 20.4 5 3.7
Height (cm) 166.4 5 8.9 163.1 5 9.3 175.2 5 8.9 159.3 5 11.6weights derived from the LBCs; (2) probe selection and weights
derived from the LifeLines DEEP cohort (3); probe selection from
the Framingham discovery and weights derived from the LBCs;
(4) probe selection from the Framingham discovery and weights
derived from the LifeLines DEEP cohort; and (5) probe selection
and weights derived from a fixed-effect meta-analysis of the
LBCs and LifeLines DEEP cohort. To estimate the proportion of
variance accounted for by the profile scores in the BSGS cohort,
we corrected the sex- and age-adjusted BMI Z scores (scores stan-
dardized within the cohort) for family structure by using a linear
mixed model (LMM) analysis in GCTA,38 in which we used
SNP genotypes to estimate pedigree relatedness (pairwise related-
ness < 0.05 was set to 0 according to the method in Zaitlen
et al.39). Residuals from this LMM analysis were used as the sex-,
age-, and family-structure-corrected BMI phenotype. The propor-
tion of variance explained in the latter phenotype by each of the
abovementioned methylation-profile scores was estimated by
linear regression.
Correcting for Cell Count
Chronic inflammation is known to be associated with obesity, and
white blood cell counts have been shown to increase with
increasing BMI.40 Although the aim of this study was to investi-
gate howmuch variation in BMI and height is captured by genetic
and methylation differences irrespective of causality, we did
perform the above analyses on cell-count-corrected methylation
data as a sensitivity analysis.Results
Cohort Characteristics
After sample QC, 1,366 samples from the LBCs (n ¼ 446
from LBC1921 and n ¼ 920 from LBC1936), 752 samples
from the LifeLines DEEP cohort, and 403 samples from
the BSGS cohort (after we removed one individual from
each MZ twin pair) had methylation, phenotype, and ge-
notype data. Cohort characteristics of these samples are
provided in Table 2. The LifeLines DEEP participants
had a much wider age range (18–81 years) and were on
average much younger (mean 45.5 5 13.3 years) than
LBC participants (69.5 5 0.8 years in LBC1936 and
79.1 5 0.6 years in LBC1921). The mean age in the
BSGS cohort was 145 2.4 years. BMI and height distribu-
tions for each cohort are shown in Figures S1 and S2. The
BMI and height phenotypes were adjusted for age and sex
in each cohort.ThMethylome-wide Association Analysis
To create a multi-probe methylation predictor, we first
conducted a methylome-wide association analysis. A total
of 431,951 and 407,935 CpG probes remained in the
LBC and LifeLines DEEP datasets, respectively, after
QC and probe filtering. Probes with an association
p value < 1.16 3 107 in the LBC dataset and a
p value < 1.22 3 107 in the LifeLines DEEP dataset
were considered to be significantly associated after Bonfer-
roni correction for the number of probes tested. After
removal of correlated probes, nine CpG probes in the
LBC dataset and five probes in the LifeLines DEEP
dataset were associated with BMI and were used for
generating methylation-profile scores (Table S1). Two
probes (cg06500161 and cg11024682) were significantly
associated with BMI in both cohorts—cg06500161 is
found in an intronic region of ABCG1 (ATP-binding
cassette, sub-family G, member 1 [MIM: 603076]), and
cg11024682 is intronic to one isoform of SREBF1 (sterol
regulatory element binding transcription factor 1 [MIM:
184756]). Both genes are known to be involved in
lipid metabolism, but neither has been identified by
GWASs to harbor genetic variants that are associated
with BMI.
For height, no CpG probes passed the p value threshold
in the LBCs, whereas only a single probe passed the
threshold in the LifeLines DEEP cohort. Therefore, to
generate a height-profile score, we used a less stringent
association p value of <0.001 for probe selection. 507
and 949 CpG probes were selected in the LBCs and
LifeLines DEEP cohort, respectively. Quantile-quantile
plots for each MWAS are shown in Figure S3. We observed
inflation in the lambda values—for BMI, lambdas were
1.53 and 1.17 in the LBCs and LifeLines DEEP cohort,
respectively, whereas for height, lambdas were 1.12 and
1.36, respectively. Lambdas close to 1 (SD ¼ 0.1) were
observed with permutation analysis (performed in both
the LBCs and LifeLines DEEP cohort), which indicates
that the inflation was due to real signal and not an artifact
of our assumption of the null distribution of the test
statistic.
Proportion of BMI and Height Variance Explained by
Profile Scores in the LBCs and LifeLines DEEP Cohort
Consistent with expectation, all methylation- and ge-
netic-profile scores were correlated with their respective
traits in the anticipated direction (Table S2). The methyl-
ation-profile scores explained 6.9% and 4.9% (p value <
1 3 1015 and 7 3 1010, respectively) of the variation
in BMI in the LBCs and LifeLines DEEP cohort, respec-
tively, whereas the genetic-profile scores explained 8.0%
and 9.4% (p value < 1 3 1015), respectively (Figure 1).
When both the methylation- and genetic-profile scores
were included in an additive model for BMI, each re-
mained independently associated with BMI. The propor-
tion of variance explained by the additive model was
14.0% and 13.6% in the LBCs and LifeLines DEEP cohort,e American Journal of Human Genetics 97, 75–85, July 2, 2015 79
Figure 1. BMI and Height Prediction
The plots depict howmuch of the variance
in the sex- and age-adjusted BMI and
height phenotypes (adjusted R2) was ex-
plained by the methylation-profile score,
the genetic-profile score, an additive
model including both scores (methyla-
tion þ genetic), and an interaction model
(methylation 3 genetic). The methylation
score in the LBCs is based on selected
probes and effects sizes from the LifeLines
DEEP MWAS, and vice versa. The genetic-
profile scores are based on results from
the GIANT meta-GWAS.respectively, suggesting a mainly additive effect of the two
scores on BMI (Figure 1).
The BMI methylation-profile scores, based on 78 probes
selected from an MWAS in the larger Framingham Heart
Study (M.M.M., unpublished data) but weighted with
effect sizes estimated in the LBCs, explained 7.3% of the
variation in BMI in the LifeLines DEEP cohort, whereas
a profile score based on the effects estimated in the
LifeLines DEEP cohort explained 11% of the variation in
the LBCs. As before, the methylation-profile scores
showed an additive effect with the genetic-profile
scores (Figure S4). Compared to the methylation-profile
scores derived from the MWAS in the LBCs or LifeLines
DEEP cohort, the larger R2 values for the profile scores
based on probes identified in the Framingham cohort
suggest that the larger sample size in the latter study pro-
vided more power to identify additional CpG probes and
hence allowed us to explain a higher proportion of vari-
ance in BMI.
The height methylation-profile scores were associated
with height and explained 0.31% and 0.76% (p value ¼
0.02 and 0.01 of the variation in the LBCs and LifeLines
DEEP cohort, respectively). The height genetic-profile
scores explained 18.5% and 19.8% (p value < 1 3 1015)
of the inter-individual variation in the height phenotype
in the LBCs and LifeLines DEEP cohort, respectively
(Figure 1). The additive model including both methyl-
ation- and genetic-profile scores explained 18.5% and
20.1% of the variation in the height phenotype in the
LBCs and LifeLines DEEP cohort, respectively. However,
the methylation-profile score showed no independent
association in the LBCs (p ¼ 0.16) and remained only
marginally associated (p ¼ 0.035) with the height pheno-80 The American Journal of Human Genetics 97, 75–85, July 2, 2015type independently of the genetic-
profile score in the LifeLines DEEP
cohort.
For BMI, the interaction model ex-
plained a slightly larger proportion
of variance than did the additive
model in the LBCs (15% versus 14%;
ANOVA p value ¼ 5 3 106) but not
in the LifeLines DEEP cohort (Table
S3). There was no significant interac-tion between the genetic- and methylation-profile scores
for height in either cohort.
Proportion of BMI Variance Explained in BSGS
Adolescent Individuals
The methylation-profile scores derived from the MWAS
analysis in the LBC individuals did not explain any varia-
tion (adjusted R2 ¼ 0.001) in the sex- and age-adjusted
BMI phenotype from the BSGS cohort, whereas that
derived from the mostly middle-aged individuals of the
LifeLines DEEP study explained 3.6% (p value ¼ 8 3
105; Figure 2). Methylation scores based on the CpG
probes identified in the larger Framingham MWAS but
weighted with effect sizes from the older LBC individuals
explained 3.0% of the variation in BMI in adolescent indi-
viduals. Based on the same CpG probes but effect sizes
derived from the younger, albeit smaller, LifeLines DEEP
cohort, the methylation-profile scores explained almost
twice (5.4%) the variation in BMI in adolescent individuals
(Figure 2).
Given that the proportion of variance explained in a pre-
diction setting is a function of sample sizes of the discovery
cohorts, the R2 values from different-sized cohorts are not
directly comparable. We therefore compared the ratio of
the methylation score R2 to the genetic score R2 to look
at the relative contribution of the methylation- and ge-
netic-profile scores to variance in BMI in both BSGS adoles-
cents and older cohorts. As shown in Table S4, in all cases,
the methylation-profile scores had a lower contribution to
BMI variance in the BSGS cohort than in the other cohorts.
The methylation predictor derived from older individuals
(probes and weights for the methylation-profile score
derived from the LBC MWAS) performed the worst.
Figure 2. BMI Prediction in BSGS Ado-
lescents
The plots show how much of the variance
in the sex- and age-adjusted BMI pheno-
type (adjusted R2) was explained by the
methylation-profile score, the genetic-pro-
file score, an additive model including
both scores (methylation þ genetic), and
an interaction model (methylation 3 ge-
netic). The GWAS scores are based on
results from the GIANT meta-GWAS.
Methylation scores are based on probe se-
lection and weights derived from the
LBCs MWAS or the LifeLines DEEP
MWAS (upper panel) or probe selection
from the Framingham discovery with
weights derived from the LBCs or LifeLines
DEEP studies (lower panel).A BMI methylation score based on a fixed-effect meta-
analysis of the LBC and LifeLines DEEP MWAS results,
whereby a Bonferroni correction for 374,629 common
probes in the two cohorts (p value < 1.33 3 107) was
used for selecting probes, performed better than the
methylation score based on the LBC MWAS. However,
despite the larger sample size, it performed worse than
the predictor based on the LifeLines DEEP MWAS: its
adjusted R2 was 0.028 (p value ¼ 4.0 3 104).
Correcting for Cell Count
In the LBCs, all cell counts except neutrophils were
associated with sex- and age-adjusted BMI (p < 0.05),
but only monocytes were associated with sex- and
age-adjusted height. In contrast, in the LifeLines DEEP
cohort, all cell counts were significantly associated
with BMI, but not with height. Adjusting for cell
count reduced some of the inflation observed in the
uncorrected analysis—for BMI, lambdas were 1.28 and
1.00 in the LBCs and LifeLines DEEP cohort, respectively,
whereas for height, lambdas were 1.00 and 1.15, respec-
tively. The proportion of variance explained by the
methylation scores after cell-count correction is shown
in Figure S5. The cell-count-corrected methylation
scores based on the MWAS discovery in the LBCs and
LifeLines DEEP cohort remained significantly associated
with BMI and showed an additive effect, although the
proportion of variance explained was substantially less
in the LBCs (3.2%). For height, the methylation-profile
score was still marginally associated with the sex- and
age-adjusted height phenotype in the LifeLines DEEP
cohort (adjusted R2 ¼ 0.0041; p value ¼ 0.045), but not
in the LBCs.The American Journal of HDiscussion
We investigated two traits that we
postulated a priori to have varying
contributions of genetic and environ-
mental factors to inter-individual
variability—we hypothesized thatheight would have a mostly genetic component, whereas
BMI would have a larger environmental contribution
that increases with age.10 We found that the methyl-
ation-profile scores contributed almost nothing to the
inter-individual variance in height but showed a strong
association with BMI. The BMI methylation-profile score
improved prediction of BMI over and above the genetic-
profile score. The two profile scores acted mostly in an
additive manner, suggesting that methylation-profile
scores capture information that is largely independent of
the genetic determinants of BMI. Our results suggest that
even if there are genetic variants whose effects on BMI
are mediated by methylation, their contribution is small.
Therefore, methylation profiles might have important util-
ity in improving phenotype prediction over and above
genetic data alone.
Furthermore, BMI methylation profiles in older people
(the LBC individuals) did not predict well in adolescents
(BSGS cohort). A methylation predictor based on CpG
probes identified in a larger, independent study (Framing-
ham) explained almost double the proportion of variance
in BMI in BSGS adolescent individuals when the effect
sizes used for generating the methylation-profile score
were derived from the younger LifeLines DEEP cohort
than when they were derived from the older LBC individ-
uals. A methylation predictor based on the meta-analysis
of the LBCs and LifeLines DEEP cohort, despite the larger
sample size, performed worse than a predictor based
on the LifeLines DEEP cohort alone. The relative contri-
bution of the methylation and genetic predictors for
BMI in adolescent individuals was also found to be
much lower. Combined, the results suggest that these
differences might be due to the direct effect of moreuman Genetics 97, 75–85, July 2, 2015 81
prolonged exposure to environmental factors in older in-
dividuals, or the fact that older individuals are ‘‘exposed’’
to the phenotype for longer, and therefore might show
larger effects on methylation due to reverse causation
(Figure S6).
The effect sizes for individual CpGs are much larger than
effect sizes for individual SNPs, and this is reflected in the
fact that the proportion of variance explained by the CpGs
identified in relatively small sample sizes (<1,500 individ-
uals) is comparable to that explained by SNPs identified
in very large samples used in genetic discovery (over
250,000 individuals). This suggests that bigger studies
might be able to identify epigenetic variation that ac-
counts for a larger proportion of the inter-individual vari-
ance of a complex trait.
A permutation analysis gives an indication of the highly
correlated structure of the methylation probes in the
genome. If lambda is the mean c2 statistic across all
~400,000 probes, then its sampling variance is 2/M, where
M is the effective number of independent probes, i.e., the
number of independent probes that give the same sam-
pling variance as the observed variance. The SD of the
genome-wide lambda from permutations therefore implies
a surprisingly small effective number of independent
methylation probes of only 2/0.12 ¼ 200, consistent
with a complex correlation structure. Such a complex cor-
relation structure or small effective number of probes does
not imply the absence of meaningful and genome-wide
biological inference, as shown, for example, for gene
expression, which is also characterized by a complex corre-
lation structure.41
A limitation of our study was the relatively small sample
size of the LBCs and LifeLines DEEP cohort. We showed
that a methylation-profile score based on a more extensive
CpG probe list identified from the larger Framingham
study performed the best. This suggests that the smaller
sample size of the LBCs and LifeLines DEEP cohort lacked
the power for statistical identification of additional CpGs.
A sensitivity analysis using different p value thresholds to
select CpG probes in the LBCs and LifeLines DEEP cohort
showed that the ability of the methylation score to predict
BMI decreased as the p value threshold was relaxed (Table
S5). Forming large consortia to enable meta-analyses of
multiple studies will overcome power issues and identify
more robust associations, as well as estimate effect sizes
more accurately. However, sample characteristics of the co-
horts would need careful consideration for methylation
analyses.
As more BMI-associated CpG sites are identified, the
interaction between methylation and genetic profiles
might become stronger, because it would be reasonable
to expect that methylation at some of these CpGs might
lie in the causal pathway, downstream of SNP effects.
Further analysis to identify SNPs associated with
both BMI and methylation levels at BMI-associated
CpG sites would be needed to dissect the observed interac-
tion and determine causality. Current work using aMende-82 The American Journal of Human Genetics 97, 75–85, July 2, 2015lian randomization approach to identify a causal SNP
(rs4925108) that is associated with methylation at a CpG
site in SREBF suggests that both the SNP and the methyl-
ation levels at the CpG appear to be associated with BMI
(M.M.M., unpublished data).
Another limitation of our study was the use of methyl-
ation profiles observed in blood. It is well known that tis-
sue-specific DNA-methylation profiles exist; therefore,
methylation profiles in blood might not be entirely repre-
sentative of other tissues. If the primary interest for identi-
fying epigenetic profiles is to determine causality, the tis-
sue under investigation might be of great importance,
and a more relevant tissue, such as adipose tissue, might
be more suitable for a trait such as BMI or obesity. This
might not apply for prediction, and comparing blood-
derived methylation predictors with those derived from
other tissues would be a logical next step if data were
available.
The SNP arrays used in the BMI and height GWASs pro-
vide comprehensive coverage of the genome: 93% of
common SNPs (both coding and non-coding) in the CEU
population (Utah residents with ancestry from northern
and western Europe from the CEPH collection) are tagged
at r2 R 0.8.42 In comparison, although the Infinium
HumanMethylation450 array comprehensively evaluates
promoter regions and CpG islands, as well as other poten-
tially relevant intergenic regions, such as regulatory re-
gions,43 it only interrogates a small subset of the~28million
CpGsites in thehumangenome. Therefore, otherCpG sites
might be missed, potentially giving an incomplete and
biased view of the relative contribution of genetic and
epigenetic factors to phenotypic variation. Despite this,
the array has already proven to be a useful high-throughput
technology for unraveling interesting biology: a number of
studies have successfully identified CpGs in or near likely
candidate genes associated with various phenotypes.
A drawback of using epigenetic disease markers, like any
other molecular biomarker, is that they are vulnerable to
confounding and reverse causation. This also applies to
cell counts as a biomarker. The observed attenuation of
the BMI variance explained by the methylation predictor
when the MWAS was adjusted for cell counts suggests
that both methylation and cell counts are involved in
either the cause or the consequence of BMI differences be-
tween individuals. Distinguishing methylation changes
that lie in the causal pathway from those that are a conse-
quence of disease is an important task for understand-
ing disease etiology and identifying new drug targets.
Combining genetic and epigenetic data in a typical Men-
delian randomization analysis might identify causal
methylation changes due to genetic variation. In the
context of BMI, methylation changes due to obesity would
still be of interest for understanding the etiology of down-
stream disease outcomes, such as cardiovascular disease or
type 2 diabetes. However, neither causality nor functional
knowledge is necessary for prediction and was therefore
not the focus of this study.
In summary, we have shown that inter-individual dif-
ferences in environment or lifestyle are partly reflected
in DNA-methylation data, and therefore DNA-methyl-
ation profiles have the potential to significantly improve
complex-trait prediction over and above that of genetic
predictors. Outside of disease association, applying accu-
rate prediction of complex traits by using genetic and
epigenetic predictors might be useful in forensic inves-
tigations where a biological sample is available but where
there is no profile from the person whose sample is
investigated.Accession Numbers
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